Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Core Viewpoint - Kamada Ltd. has launched a new post-marketing research program to generate data supporting the benefits of CYTOGAM® in managing cytomegalovirus (CMV) in solid organ transplantation [1][3] Research Program Overview - The research program aims to advance CMV disease management through strategies focused on late-onset CMV prevention, alternative dosing strategies, and potential new applications of CYTOGAM [2] - It includes health economic studies to analyze the cost burden of CMV in solid organ transplantation and a clinical practice study on current CMV management in lung transplantation [2][6] Clinical Data and Collaborations - Kamada has engaged Key Opinion Leaders (KOLs) to study clinical experiences with CYTOGAM, presenting findings at various medical conferences [4] - Notable studies include a five-year retrospective cohort study on lung-transplant patients and an analysis of stored samples from a previous randomized controlled study, demonstrating CYTOGAM's potential benefits [4] Financial Performance - For the year ended December 31, 2024, Kamada reported revenues of $22.5 million from CYTOGAM sales, reflecting a 31% increase from the previous fiscal year [3] Product Information - CYTOGAM is the only FDA-approved immunoglobulin product for the prophylaxis of CMV disease associated with solid organ transplantation [5]